Travere director exercises options, sells 10K shares
Travere Therapeutics director Roy D. Baynes exercised and sold shares in a planned transaction.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Travere Therapeutics director Roy D. Baynes exercised and sold shares in a planned transaction. On April 6, 2026, he exercised stock options for 10,000 shares of Common Stock at an exercise price of $26.52 per share and received 10,000 shares.
That same day, he completed an open-market sale of 10,000 Common Stock shares at $33.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 17, 2025. Following these transactions, Baynes directly holds 37,500 Common Stock shares.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($65K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Baynes Roy D.
Role
Director
Sold
10,000 shs ($330K)
Approx. gross sale proceeds
$330K
Approx. exercise cost
$265K
Approx. pre-tax spread
$65K
Share of Position Sold
21.1%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $26.52 | $265K |
| Sale | Common Stock | 10,000 | $33.00 | $330K |
Holdings After Transaction:
Stock option (right to buy) — 0 options (Direct);
Common Stock — 37,500 shares (Direct)
Holdings Before and After:
Stock option (right to buy), 10,000 to 0 options (Direct);
Common Stock, 37,500 to 37,500 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (2)
- F1. This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2018.
- F2. The stock option is fully vested and exercisable.
Key Figures
Options exercised: 10,000 shares
Exercise price: $26.52 per share
Shares sold: 10,000 shares
+4 more
7 metrics
Options exercised
10,000 shares
Stock option exercise on April 6, 2026
Exercise price
$26.52 per share
Stock option exercise for 10,000 underlying shares
Shares sold
10,000 shares
Open-market sale on April 6, 2026
Sale price
$33.00 per share
Price for 10,000 Common Stock shares sold
Shares owned after transactions
37,500 shares
Direct Common Stock holdings following April 6, 2026 trades
Rule 10b5-1 plan adoption date
November 17, 2025
Date written trading plan was adopted
Option grant date
May 9, 2018
Grant date of fully vested stock option exercised
Key Terms
Rule 10b5-1(c), stock option, Common Stock, open-market sale, +1 more
5 terms
Rule 10b5-1(c) regulatory
"written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
stock option financial
"consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2018"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Common Stock financial
"underlying security title: Common Stock and sale of 10,000 shares of Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
open-market sale financial
"transaction_code_description: Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
fully vested and exercisable financial
"The stock option is fully vested and exercisable"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did TVTX director Roy D. Baynes report?
Roy D. Baynes reported exercising stock options for 10,000 Travere Therapeutics (TVTX) shares at $26.52 each, then selling 10,000 Common Stock shares at $33.00 per share. After these transactions, he directly holds 37,500 Travere Therapeutics Common Stock shares.
Was the Travere Therapeutics (TVTX) insider sale made under a Rule 10b5-1 plan?
Yes. The 10,000-share sale by Roy D. Baynes was executed under a written trading plan adopted on November 17, 2025 that meets Rule 10b5-1(c) requirements. Such pre-arranged plans are designed to systematize trades over time regardless of near-term market conditions.
What prices were involved in Roy D. Baynes’ Travere Therapeutics (TVTX) Form 4 transactions?
Roy D. Baynes exercised stock options at an exercise price of $26.52 per share for 10,000 underlying shares and then sold 10,000 Common Stock shares at $33.00 per share. These prices define the economic terms disclosed for his April 6, 2026 transactions.
What derivative security did Roy D. Baynes exercise in the Travere Therapeutics (TVTX) filing?
He exercised a fully vested stock option covering 10,000 Travere Therapeutics Common Stock shares at an exercise price of $26.52 per share. The option, originally granted on May 9, 2018, was fully vested and exercisable at the time of the reported transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
